Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9229
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFrancisco Gutie´rrez-Bautista, Juan-
dc.contributor.authorRodriguez-Nicolas, Antonio-
dc.contributor.authorRosales-Castillo, Antonio-
dc.contributor.authorngel Lo´pez-Ruz, Miguel A´-
dc.contributor.authorMarı´a Martı´n-Casares, Antonia-
dc.date.accessioned2024-12-18T04:19:33Z-
dc.date.available2024-12-18T04:19:33Z-
dc.date.issued2022-06-01-
dc.identifier.issn1684-1182-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9229-
dc.description.abstractAbstract Background: Human leukocyte antigen (HLA) plays an important role in immune responses to infections, especially in the development of acquired immunity. Given the high degree of polymorphisms that HLA molecules present, some will be more or less effective in controlling SARS-CoV-2 infection. We wanted to analyze whether certain polymorphisms may be involved in the protection or susceptibility to COVID-19. Methods: We studied the polymorphisms in HLA class I (HLA-A, -B and -C) and II (HLA-DRB1 and HLA-DQB1) molecules in 450 patients who required hospitalization for COVID-19, creating one of the largest HLA-typed patient cohort to date. Results: Our results show that there is no relationship between HLA polymorphisms or haplotypes and susceptibility or protection to COVID-19.Conclusion: Our results may contribute to resolve the contradictory data on the role of HLA polymorphisms in COVID-19 infectionen_US
dc.language.isoenen_US
dc.publisherElsevier Taiwan LLCen_US
dc.subjectHLA polymorphisms;en_US
dc.subjectCOVID-19;en_US
dc.subjectSARS-CoV-2en_US
dc.titleStudy of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patientsen_US
dc.typeArticleen_US
Appears in Collections:VOL 55 NO 3 2022

Files in This Item:
File Description SizeFormat 
421-427.pdf341.52 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.